WaveMan
WaveMan · Company
IRTC · Irhythm Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IRTC iRhythm (IRTC) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001388658
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
165
13F, latest reported quarter

What the filings say about IRTC

Insiders, 180 days
-$8.7M net sold
1 buyer · 12 sellers · 0% of sales under a 10b5-1 plan

iRhythm insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, iRhythm Holdings, Inc. insiders sold a net $8.7M of stock across 180 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Wilson Daniel G.
Chief Financial Officer
SELL
2026-09-03 SECtraded 2026-09-02
773
$94.2K
-0.9%
Context
  • 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on Mar 2, 2026.
  • The trade is 2.2% of the 34,887 shares held after it.
  • 7 other insiders sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Wilson Daniel G. sold about $94.2K of IRTC on Sep 2, 2026; 7 other insiders sold within 30 days and 165 funds added in the latest 13F quarter.
Shrishrimal Sumi
EVP, Chief Risk Officer
SELL
2026-08-11 SECtraded 2026-08-10
5,372
$669.6K
-2.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 2, 2026.
  • The trade is 12.0% of the 44,621 shares held after it.
  • 7 other insiders sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Risk Officer Shrishrimal Sumi sold about $669.6K of IRTC on Aug 10, 2026; 7 other insiders sold within 30 days and 165 funds added in the latest 13F quarter.
Turakhia Minang
CHIEF MED/SCI OFCR EVP ADVTECH
SELL
2026-08-11 SECtraded 2026-08-10
7,093
$884.2K
-2.7%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jul 2, 2026.
  • The trade is 11.8% of the 60,116 shares held after it.
  • 7 other insiders sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang sold about $884.2K of IRTC on Aug 10, 2026; 7 other insiders sold within 30 days and 165 funds added in the latest 13F quarter.
Murphy Patrick Michael
CBO and CLO
SELL
2026-08-11 SECtraded 2026-08-10
7,093
$884.2K
-2.7%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Mar 2, 2026.
  • The trade is 10.2% of the 69,699 shares held after it.
  • 7 other insiders sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CBO and CLO Murphy Patrick Michael sold about $884.2K of IRTC on Aug 10, 2026; 7 other insiders sold within 30 days and 165 funds added in the latest 13F quarter.
Patterson Chad
CHIEF COMM & PRODUCT OFFICER
SELL
2026-08-11 SECtraded 2026-08-10
7,093
$884.2K
-2.7%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (1 buy, 17 sales), the last on Aug 3, 2026.
  • The trade is 11.4% of the 62,125 shares held after it.
  • 7 other insiders sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF COMM & PRODUCT OFFICER Patterson Chad sold about $884.2K of IRTC on Aug 10, 2026; 7 other insiders sold within 30 days and 165 funds added in the latest 13F quarter.
180 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 175 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$8.7M over 180 days
-$7.4M over 90 days
below 84% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
165 funds bought in last quarter
more than 77% of Medical Devices
Revenue
+26.2% year over year
more than 77% of Medical Devices
Margin
-6.0% net margin
more than 63% of Medical Devices
Buybacks
no share repurchases reported
Short interest
10.0% of the float short (float per yahoo 2026-10-26) · 5.8 days to cover · settled 2026-09-30
more than 85% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IRTC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.1%12M
-44%-28%-12%+4%2025-102025-122026-022026-042026-062026-082026-10 2026-02-25 · Blackford Quentin S. sold $3.5M2026-08-10 · Blackford Quentin S. sold $3.3M2025-11-03 · Blackford Quentin S. sold $2.6M2025-10-31 · Wilson Daniel G. sold $1.7M2026-02-25 · Patterson Chad sold $1.2M2026-02-25 · Murphy Patrick Michael sold $1.1M2026-02-25 · Turakhia Minang sold $1.1M2026-08-10 · Patterson Chad sold $884.2K2026-08-10 · Murphy Patrick Michael sold $884.2K2026-08-10 · Turakhia Minang sold $884.2K2026-02-25 · Shrishrimal Sumi sold $841.9K2026-02-25 · Wilson Daniel G. sold $702.6K2026-03-02 · Blackford Quentin S. sold $696.5K2026-08-10 · Shrishrimal Sumi sold $669.6K2026-02-25 · Rosenbaum Marc Wade sold $649.6K2026-03-02 · Blackford Quentin S. sold $558.3K2026-02-25 · Smith Mervin sold $547.2K2026-03-02 · Blackford Quentin S. sold $519.3K2025-12-02 · Murphy Patrick Michael sold $458.0K2026-03-02 · Patterson Chad sold $389.2K2026-08-03 · Patterson Chad sold $331.2K2026-03-16 · Smith Mervin sold $295.5K2025-11-10 · TALWALKAR ABHIJIT Y sold $276.4K2026-05-11 · TALWALKAR ABHIJIT Y sold $270.6K2026-03-02 · Murphy Patrick Michael sold $260.5K2026-08-03 · Rodda Julianne sold $257.9K2025-11-10 · TALWALKAR ABHIJIT Y sold $254.9K2026-02-23 · TALWALKAR ABHIJIT Y sold $250.7K2026-02-23 · TALWALKAR ABHIJIT Y sold $241.7K2025-11-10 · TALWALKAR ABHIJIT Y sold $227.4K2026-02-23 · TALWALKAR ABHIJIT Y sold $197.6K2026-03-02 · Turakhia Minang sold $191.0K2026-06-02 · Shrishrimal Sumi sold $185.7K2026-03-02 · Patterson Chad sold $181.6K2026-07-02 · Turakhia Minang sold $177.5K2026-03-02 · Turakhia Minang sold $168.3K2026-03-02 · Wilson Daniel G. sold $162.0K2026-03-02 · Turakhia Minang sold $158.0K2026-03-02 · Murphy Patrick Michael sold $152.8K2026-03-02 · Murphy Patrick Michael sold $146.3K2026-05-11 · TALWALKAR ABHIJIT Y sold $136.7K2026-03-02 · Shrishrimal Sumi sold $125.6K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IRTC: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
2,985,667 sh
$355.1M
RTW INVESTMENTS, LP
2,182,631 sh
$259.6M
VANGUARD PORTFOLIO MANAGEMENT LLC
1,913,976 sh
$227.7M
Artisan Partners Limited Partnership
1,660,307 sh
$197.5M
VANGUARD CAPITAL MANAGEMENT LLC
1,463,211 sh
$174.0M

Congress trades in IRTC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IRTC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IRTC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X HealthTech ETF
$877.6K position · as of 2026-05-31
3.5%
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$5.4M position · as of 2026-07-31
2.3%
Eventide Gilead Fund
$69.3M position · as of 2026-06-30
2.0%
Eventide Healthcare & Life Sciences Fund
$33.0M position · as of 2026-06-30
1.8%
Select Medical Technology and Devices Portfolio
$51.3M position · as of 2026-05-31
1.7%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.6M position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Quentin Blackford
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$9.3M
$1.3M
$3.0M
-62%
-21%
2023
$16.6M
$16.3M
$5.4M
-55%
-25%
2022
$8.0M
$5.3M
$4.4M
-61%
-21%
2020
$4.9M
$24.3M
$1.8M
+248%
+33%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $8.7M sold by insiders over 180 days, 165 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

IRTC financials

Revenue growth
+26.2%
XBRL, annual
Net margin
-6.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$825.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$39.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2024-12-31 (18 months older than the period end) plus current 2022-12-31 (42 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-9.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-1.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-2.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$3.8B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
+1.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$747.1M$591.8M$492.7M$410.9M
Gross profit$527.2M$407.5M$331.8M$281.6M
Operating income-$57.4M-$115.5M-$125.2M-$113.8M
Net income-$45.0M-$113.0M-$123.0M-$116.0M
EPS (diluted)-1.39-3.63-4.04-3.88
Operating cash flow$80.9M$3.4M-$50.1M-$23.0M
Cash$236.0M$419.6M$36.2M$78.8M
Long-term debtn/a$0$35.0M$34.9M
Buybacks$0$25.0M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

IRTC Stock Sonar score 6/7 axes

Find similar shapesCompare

IRTC ranks highest on financial health (99th percentile) and growth (77th), and lowest on insider conviction (32nd), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
63
Inputs
  • Return on equity-9.9% · 58 pct, sector of 183
  • Return on assets-1.4% · 67 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-2.9% · 64 pct, sector of 188
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 159
  • Cash flow to debtno debt to cover
Growth
77
Inputs
  • Revenue growth, YoY+26.2% · 77 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
32
Inputs
  • Net Form 4 buying (codes P and S), 180d-$8.7M · 12 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
77
Inputs
  • Funds adding, latest quarter165 · 77 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+10.0% · 19 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.8% · 30 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IRTC filings, in plain words

Are iRhythm insiders buying or selling IRTC?

In the 180 days to 2026-10-28, iRhythm insiders were net sellers, a net $8.7M: $56.9K of purchases and $8.7M of sales reported on Form 4, by 1 buyer and 12 sellers.

Read the full summary

In the 180 days to 2026-10-28, iRhythm insiders were net sellers of IRTC, a net $8.7M across purchases and sales reported on Form 4 by 1 buyer and 12 sellers. Sales outweighed purchases more than tenfold by value. None of the 19 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies